Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection

References

• Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol. 1999;31:17–24.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.
   PubMed Web of Science ®Google Scholar
• Shebl FM, Pfeiffer RM, Buckett D, et al. IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis. 2011;204(12):1843–1847.
   PubMed Web of Science ®Google Scholar
• Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–171.
   PubMed Web of Science ®Google Scholar
• Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405–408.
   PubMed Web of Science ®Google Scholar
• Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111(4–5):360–367.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Lorenz K, Oellerich M, et al. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem. 2006;52(2):240–247.
   PubMed Web of Science ®Google Scholar
• Rembeck K, Waldenstrom J, Hellstrand K, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2014;59(6):2131–2139.
   PubMed Web of Science ®Google Scholar
• Nystrom K, Wanrooij PH, Waldenstrom J, et al. Inosine triphosphate pyrophosphatase dephosphorylates ribavirin triphosphate and reduced enzymatic activity potentiates mutagenesis in hepatitis C virus. J Virol. 2018;92(19):e01087-18.
   PubMed Web of Science ®Google Scholar
• Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008;372(9635):321–332.
   PubMed Web of Science ®Google Scholar
• Blome MA, Bjorkman P, Flamholc L, et al. Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program. J Viral Hepat. 2011;18(12):831–839.
   PubMed Web of Science ®Google Scholar
• Kaberg M, Naver G, Hammarberg A, et al. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange – importance for HCV elimination. J Viral Hepat. 2018;25(12):1452–1461.
   PubMed Web of Science ®Google Scholar
• Abdel-Hamid M, El-Daly M, Molnegren V, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol. 2007;88(5):1526–1531.
   PubMedGoogle Scholar
• Rembeck K, Alsio A, Christensen PB, et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One. 2012;7(1):e29370.
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
   PubMed Web of Science ®Google Scholar
• Gauthiez E, Habfast-Robertson I, Rueger S, the Swiss Hepatitis C Cohort Study, et al. A systematic review and meta-analysis of HCV clearance. Liver Int. 2017;37(10):1431–1445.
   PubMed Web of Science ®Google Scholar
• Grebely J, Page K, Sacks-Davis R, the InC3 Study Group, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109–120.
   PubMed Web of Science ®Google Scholar
• Biswas A, Firdaus R, Gupta D, et al. Interferon lambda3 gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia. Transfusion. 2017;57(6):1376–1384.
   PubMed Web of Science ®Google Scholar
• Sacks-Davis R, Grebely J, Dore GJ, et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection–the InC3 study. J Infect Dis. 2015;212(9):1407–1419.
   PubMed Web of Science ®Google Scholar
• Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338–349.
   PubMed Web of Science ®Google Scholar
• Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151.
   PubMedGoogle Scholar
• Liao JY, Thakur SA, Zalinger ZB, et al. Inosine-containing RNA is a novel innate immune recognition element and reduces RSV infection [Research Support, N.I.H., Intramural]. PloS One. 2011;6(10):e26463.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457.
   PubMed Web of Science ®Google Scholar
• Brenndorfer ED, Brass A, Karthe J, et al. Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy. JI. 2014;192(4):1671–1680.
   Google Scholar
• Hultgren C, Milich DR, Weiland O, et al. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 1998;79(10):2381–2391.
   PubMedGoogle Scholar
• Alanko Blome M, Bjorkman P, Molnegren V, et al. Hepatitis C viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs. PLoS One. 2014;9(5):e97022.
   PubMed Web of Science ®Google Scholar